Clicky

Organogenesis Holdings Inc.(ORGO)

Description: Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company's pipeline products include TransCyte for the treatment of second- and third-degree burns; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor for the treatment of chronic and acute wounds; Gintuit for the treatment of mucogingival conditions in adults; and PuraPly XT and PuraPly MZ for the treatment of chronic and acute wounds, as well as for surgical treatment of open wounds. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices. The company sells its products through direct sales representatives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.


Keywords: Medicine Clinical Medicine Surgery Organ Systems Regenerative Medicine Wound Ulcer First Aid Burns Collagen Spine Acute Pain Wound Care Products Sports Medicine Medicine Products Venous Ulcer Surgical Treatment Diabetic Foot Ulcer Surgical Applications Diabetic Foot Ulcers Venous Leg Ulcers Chronic And Acute Wounds Wound Bed Preparation

Home Page: organogenesis.com

ORGO Technical Analysis

85 Dan Road
Canton, MA 02021
United States
Phone: 781 575 0775


Officers

Name Title
Mr. Gary S. Gillheeney Sr. Pres, CEO & Director
Mr. David C. Francisco Chief Financial Officer
Mr. Patrick Bilbo Chief Operating Officer
Ms. Lori H. Freedman B.A., Esq., J.D. VP & Gen. Counsel
Mr. Kurt Matheson VP of Marketing
Mr. Thomas L. Pearl VP of HR
Dr. Zorina Pitkin Sr. VP of Quality Systems
Mr. Brian Grow Chief Commercial Officer
Mr. William R. Kolb CPA Sec.

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 12.3153
Trailing PE: 6.0217
Price-to-Book MRQ: 1.3841
Price-to-Sales TTM: 0.7167
IPO Date: 2017-01-05
Fiscal Year End: December
Full Time Employees: 950
Back to stocks